By Chris Wack
Intellia Therapeutics shares were up 10% at $26.10 after the European Commission granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema.
The stock hit its 52-week low of $22.67 on Monday, and is down 51% in the past 12 months.
NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.
Orphan drug designation in the European Union is granted by the EC based on a positive opinion issued by the European Medicines Agency Committee for Orphan Medicinal Products. To qualify for orphan drug designation, a candidate therapy must be intended for the treatment, prevention or diagnosis of a life-threatening or chronically debilitating disease that occurs in not more than five in 10,000 people in the EU.
Intellia has received five special regulatory designations for NTLA-2002. NTLA-2002 was also granted Orphan Drug Designation by the U.S. Food and Drug Administration.
Write to Chris Wack at [email protected]
Read the full article here
